Live Breaking News & Updates on Department Of Medical Oncology At Vall

Stay updated with breaking news from Department of medical oncology at vall. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AstraZeneca: CHMP green light for Truqap + Faslodex

AstraZeneca announces that Truqap in combination with Faslodex has been recommended by the Committee for Medicinal Products for Human Use of the European Medicines Agency for approval in the. ....

Israel General , Comunidad Autonoma De Cataluna , Mafalda Oliveira , Hebron Oncology Institute , European Union , Committee For Medicinal Products Human Use , Breast Cancer Group , Department Of Medical Oncology At Vall , European Medicines Agency , Hebron University Hospital , Medicinal Products , Human Use , Senior Consultant , Medical Oncology , Senior Clinical Researcher ,

CHMP Recommends Capivasertib/Fulvestrant for Pretreated ER+/HER2– Advanced Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

The EMA’s CHMP recommended capivasertib/fulvestrant for ER-positive, HER2-negative advanced breast cancer harboring PIK3CA, AKT1, or PTEN alterations. ....

Israel General , Comunidad Autonoma De Cataluna , Mafalda Oliveira , Department Of Medical Oncology At Vall , Hebron University Hospital , Hebron Institute Of Oncology Breast Cancer Group , European Medicines Agency , Medicinal Products , Human Use , Medical Oncology , Hebron Institute , Breast Cancer Group , Er Positive Breast Cancer , Pik3ca Alterations , Akt1 Alterations , Pten Alterations ,

Truqap Plus Faslodex Boosts Breast Cancer Outcomes, Quality of Life

Patients with HR-positive, HER2-negative breast cancer tended to have longer health-related quality of life and improved outcomes with Truqap plus Faslodex, research showed. ....

San Antonio , United States , Truqap Faslodex , Mafalda Oliveira , Truqap Faslodec , Department Of Medical Oncology At Vall , Hebron University Hospital , Antonio Breast Cancer Symposium , Patient Global Impression , Truqap Faslodex Offers , More Option , Some With Breast Cancer , Medical Oncology , Treatment Tolerability , Breast Cancer ,

Capivasertib Maintains QOL Benefit Vs Placebo in HR+/HER2– Advanced Breast Cancer

Capivasertib plus fulvestrant did not negatively affect quality of life compared with placebo plus fulvestrant in patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer.
....

San Antonio , United States , Capivasertib Truqap , Mafalda Oliveira , Department Of Medical Oncology At Vall , Hebron University Hospital , Antonio Breast Cancer , Medical Oncology , Patient Global Impression , Treatment Tolerability , Capivasertib Plus Fulvestrant , Patients With Hormone Receptor Positive , Her2 Negative Breast Cancer , Capitello 291 Trial , Valld X27 Hebron University Hospital ,